Peptides and Heart Health: What Current Research Shows
Several peptides have been studied for heart health, but the level of evidence varies significantly. Some are still experimental research compounds while others have been tested in larger clinical trials. The most commonly discussed peptides in cardiovascular research include thymosin beta 4, elamipretide also known as SS 31, apelin peptides, relaxin based therapies, and natriuretic peptides such as BNP and ANP analogs. Thymosin beta 4 is one of the most studied peptides for cardiac repair. Most of the research focuses on heart attack recovery and ischemic injury. Preclinical studies show that it may help reduce inflammation, support blood vessel growth, and improve cardiac remodeling after injury. Human research is still limited and results so far suggest it remains an investigational approach rather than an established therapy. Elamipretide, also known as SS 31, is a mitochondria targeted peptide that has been studied in heart failure and mitochondrial dysfunction. Early human trials suggest it may improve mitochondrial energy production in heart cells and influence cardiac function, although results across studies have been mixed. Apelin peptides are natural signaling molecules involved in blood pressure regulation, cardiac contractility, and vascular health. Early clinical research shows they can improve short term cardiac output and heart performance in heart failure settings. Several apelin receptor agonists are currently being studied as potential therapies. Relaxin based therapies such as serelaxin have been studied in acute heart failure. Early trials showed improvements in symptoms and some cardiovascular markers, but larger studies did not demonstrate clear reductions in mortality or long term heart failure outcomes. Natriuretic peptides have the longest clinical research history in cardiology. These include BNP and ANP based drugs such as nesiritide and carperitide. They help regulate fluid balance, blood pressure, and vascular tone and have been studied extensively in acute heart failure, although long term outcome benefits have been inconsistent.